



touchREVIEWS in Oncology & Haematology

VOLUME 19 • ISSUE 1 • 2023

EDITOR-IN-CHIEF: AXEL S MERSEBURGER

**Pan-RAF Inhibitors for Paediatric Low-grade Gliomas
Offer New Opportunities in Targeted Therapy**

David S Ziegler

**Tailoring the Treatment of Early-stage HER2-positive
Breast Cancer: One Size Does Not Fit All**

Ilana Schlam, Paolo Tarantino, Adrienne Waks,
Sara M Tolaney

**Nivolumab Combination Therapy for the Treatment of
Unresectable Advanced or Metastatic Oesophageal
Squamous Cell Carcinoma**

Yuri Yoshinami, Shun Yamamoto, Ken Kato

**Teclistamab Monotherapy for the Treatment of Adult
Patients with Relapsed and Refractory Multiple Myeloma**

Beatrice M Razzo and Alfred L Garfall

www.touchONCOLOGY.com

touchREVIEWS

in Oncology & Haematology

Volume 19 • Issue 1 • 2023

Cover image: Group of isolated cancer cells -
3d illustration. Generative AI.
©stock.adobe.com



touchREVIEWS in Oncology & Haematology wishes to thank the organizations below for their assistance. This does not constitute any official endorsement.



Senior Editorial Director

Gina Furnival

Editorial Directors

Katey Gabrysch
Sophie Nickelson

Commissioning Editors

Victoria Jones
Shanice Allen

Editorial Workflow

Lisa Glass
Heather Hall
Atiya Henry
Marianna Mignani
Danielle Crosby

Head of Medical & Editorial

Nicola Cartridge
E: nicola.cartridge@touchmedicalmedia.com
T: +44 (0)20 7193 3186

CEO & Managing Director

Barney Kent
E: barney.kent@touchmedicalmedia.com
T: +44 (0)20 7193 3009

Head of Strategic Partnerships

Caroline Markham
E: caroline.markham@touchmedicalmedia.com
T: +44 (0)20 7193 3704

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2023 Touch Medical Media Services Limited, a private limited company registered in England and Wales at Lancashire Gate, 21 Tiviot Dale, Stockport, Cheshire, SK1 1TD with registered number 12930327. All rights reserved. eISSN: 2752-5481



www.touchmedicalmedia.com

touchREVIEWS

in Oncology & Haematology

Editors-in-Chief

Axel S Merseburger

Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

Matti S Aapro

Multidisciplinary Cancer Institute, Genolier, Switzerland

Eleni Andreopoulou

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Editorial Board

Mohammad Ammad-Ud-Din

Rochester General Hospital, Rochester, NY, USA

Ahmad Awada

Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Wadie F Bahou

State University of New York, Stony Brook, NY, USA

Tanios Bekaii-Saab

Mayo Clinic, Phoenix, AZ, USA

Raffaele Califano

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Ezra Cohen

University of Chicago Medical Center, Georgetown University, Chicago, IL, USA

Jorge Cortes

Georgia Cancer Center, Augusta University, Augusta, GA, USA

Véronique Diéras

Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

Massimo Dominici

Medical Oncology, University Hospital of Modena, Modena, Italy

Martin J Edelman

Fox Chase Cancer Center, Philadelphia, PA, USA

Dean A. Fennell

Leicester Cancer Research Centre, Genetics & Genome Biology, University of Leicester, UK

Willem E Fibbe

Department of Immuno-haematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands

Robin Foà

Institute of Hematology, 'La Sapienza' University of Rome, Rome, Italy

Paolo A Ascierto

Unit of Melanoma, ational Tumor Institute 'Fondazione G Pascale', Naples, Italy

John L Marshall

Lombardi Comprehensive Cancer Center, Washington, DC, USA

Michael K Gibson

University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA

Charlie Gourley

Cancer Research UK Edinburgh Center; Nicola Murray Centre for Ovarian Cancer Research, The University of Edinburgh, Scotland, UK

Axel Grothey

West Cancer Center, Germantown, TN, USA

Martin Hutchings

The Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Claudine Isaacs

Lombardi Comprehensive Cancer Center, Georgetown University, Chicago, IL, USA

Elias Jabbour

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ken Kato

National Cancer Center Hospital, Tokyo, Japan

Daniel Kelly

Royal College of Nursing, School of Healthcare Sciences, Cardiff University, Cardiff, UK

Ticiana Leal

Emory University School of Medicine, Atlanta, GA, USA

Charles D Lopez

Oregon Health & Science University, Portland, OR, USA

Domenica Lorusso

Catholic University of Rome, Rome, Italy

Mario Mandalà

Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Pier Mannuccio Mannucci

Maggiore University Hospital of Milan; Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy

John L Marshall

MedStar Georgetown University Hospital, Washington, DC, USA

David G Mutch

Washington University School of Medicine, St Louis, MO, USA

Maurice Pérol

Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center, Lyon, France

Bruce Minsky

University of Texas MD Anderson Cancer Center, Houston, TX, USA

Michael J Morris

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Suchita Pakkala

Emory University School of Medicine, Atlanta, GA, USA

Bernardo Rapoport

The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Andrew I Schafer

Weill Cornell Medical College, New York, NY, USA

Emma Searle

The Christie Hospital NHS Foundation Trust, Manchester, UK

Lena Sharp

Regional Cancer Center, Stockholm, Sweden

Gerard Socié

Department of Bone Marrow Transplantation, Hospital Saint-Louis, Paris, France

Sara M Tolaney

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Ulka Vaishampayan

Wayne State University, Detroit, MI, USA

Benjamin Weinberg

Ruesch Center for the Cure of Gastrointestinal Cancers; Lombardi Comprehensive Cancer Center, Washington, DC, USA

Antoinette J Wozniak

Wayne State University; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

touchREVIEWS

in Oncology & Haematology

Established: January 2005 Frequency: Bi-annual
Current edition: Volume 19 Issue 1, 2023

Aims and scope

- *touchREVIEWS in Oncology & Haematology* enables time-pressed physicians to stay abreast of major advances and opinions in oncology and haematology practice.
- *touchREVIEWS in Oncology & Haematology* comprises balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the oncology and haematology fields.
- *touchREVIEWS in Oncology & Haematology* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in Oncology & Haematology* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICJME, GPP 2022, and COPE guidelines.

Structure and format

- *touchREVIEWS in Oncology & Haematology* is a peer-reviewed, free-to-access, bi-annual journal comprising review articles, editorials, special reports and original research.
- The structure of each edition of the publication comprises section categories determined by the Editor. The degree of coverage assigned to each category is the decision of the Editor, and in part reflects the views of the Editorial Board.
- All articles state any author disclosures along with any funding, financial support and/or medical writing assistance.
- Each edition of *touchREVIEWS in Oncology & Haematology* is published in full, online at: www.touchONCOLOGY.com

Editorial expertise

touchREVIEWS in Oncology & Haematology is supported by various levels of expertise:

- Guidance from an Editorial Board consisting of leading authorities from a variety of oncology and haematology disciplines.
- Invited contributors who are recognized authorities in their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of editors and technical editors.

Peer review

- On submission, all articles are assessed by the Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Editor identifies appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.
- We aim to have the final peer review decision within 4 weeks.
- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes, or not accepted for publication.

- The Editor reserves the right to accept or reject any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and instructions for authors

- The Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Editor for further details: editorialmanager@touchmedicalmedia.com
- Instructions for authors are available on the website: www.touchONCOLOGY.com

Distribution and readership

touchREVIEWS in Oncology & Haematology is distributed globally, on a bi-annual basis, through controlled circulation to senior professionals in the field globally.

Free-to-access

All articles are free-to-access, which allows anyone in the oncology and haematology field to download published articles free of charge.

Abstracting and indexing

touchREVIEWS in Oncology & Haematology is abstracted, indexed and listed in Embase, EBSCO, Genamics JournalSeek, Google Scholar, IndexCopernicus and Summon by Serial Solutions.

Copyright

Authors transfer copyright of their article to Touch Medical Media, who publish the article as free-to-access to registered users.


Online resources

www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resources across nine therapy areas including cardiology, endocrinology, haematology, immunology, infectious diseases, neurology, oncology, ophthalmology and respiratory and pulmonary medicine.


Society partners

touchONCOLOGY has developed very valuable partnerships with the most respected not-for-profit medical societies both in Europe and the USA. These partnerships are key as touchONCOLOGY.com helps to promote awareness of these medical societies whilst also providing free-to-access, peer-reviewed articles and multimedia content to society members, which ensures that the industry is kept up to date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media

Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reviewed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals. 





Foreword

1 Foreword

Benjamin Weinberg

Georgetown University, Washington, DC, USA

Expert Interview

Lung Cancer

2 Pafolacianine: A Diagnostic Agent to Identify Lung Cancer Lesions in Adults with Known or Suspected Lung Cancer

Linda W. Martin

Department of Surgery, Thoracic Surgery Division, University of Virginia School of Medicine, VA, USA

Editorial

Paediatric Oncology

4 Pan-RAF Inhibitors for Paediatric Low-grade Gliomas Offer New Opportunities in Targeted Therapy

David S Ziegler^{1,2,3}

1. Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia; 2. Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Australia; 3. School of Clinical Medicine, UNSW Medicine and Health, UNSW Sydney, Australia

Reviews

Breast Cancer

6 Trastuzumab Deruxtecan for the Treatment of HER2-positive Breast Cancer

Toshinari Yamashita

Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan

11 Tailoring the Treatment of Early-stage HER2-positive Breast Cancer: One Size Does Not Fit All

Ilana Schlam,¹ Paolo Tarantino,^{2,3} Adrienne Waks² and Sara M Tolaney²


1. Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA; 2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; 3. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, University of Milan, Milan, Italy

Gastrointestinal Oncology

17 Nivolumab Combination Therapy for the Treatment of Unresectable Advanced or Metastatic Oesophageal Squamous Cell Carcinoma

Yuri Yoshinami, Shun Yamamoto and Ken Kato

Department of Head and Neck, Oesophageal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan



22 **Durvalumab: A PD-L1 Blocking Antibody for the Treatment of Adult Patients with Locally Advanced or Metastatic Biliary Tract Cancer**

Amit Mahipal,^{1,2} Mathias Palmer,¹ Jennifer Gile¹ and Richard Kim³

1. Department of Oncology, Mayo Clinic, Rochester, MN, USA; 2. Department of Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA; 3. Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA

Genitourinary Oncology

27 **The Evolving Therapeutic Landscape and Role of Enfortumab Vedotin in Advanced Urothelial Carcinoma: A Systematic Review**

Rafee Talukder,¹ Dimitrios Makrakis,² Petros Grivas¹ and Ali Raza Khaki³

1. Department of Medicine, Division of Oncology, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA; 2. Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, NY, USA; 3. Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA

Haematology

35 **Sutimlimab for the Treatment of Cold Agglutinin Disease**

Ilene Weitz

Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine Los Angeles, Los Angeles, CA, USA

Immunotherapy

41 **Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma**

Justin Mencil and Sheela Rao

Gastrointestinal Unit, Royal Marsden NHS Foundation Trust, London, UK

Haematological Malignancies

46 **Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma**

Beatrice M Razzo and Alfred L Garfall

Abramson Cancer Center and Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA